Skip to content
Head to head

Biohaven vs Vertex Pharmaceuticals

Side-by-side on the measures that matter, with a plain-English read. Full detail: BHVN · VRTX

Updated 9 minutes ago

1-year performance, rebased to 100

BHVN +49.8%VRTX +18.7%
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
BHVNVRTX
Snapshot
Sector--Biotechnology
Last price12.39515.02
Change today-9.23%-1.08%
1-year return+28.7%+22.0%
Market cap$1.87B$130.58B
52-week range8.03 – 18.24412.27 – 568.67
Valuation
P/E (TTM)-3.2933.14
P/E percentile, own 5-yr range47th99th
P/B-19.066.25
Dividend yield0.00%0.00%
Profitability & growth
EPS (TTM)-6.8615.32
Net profit (TTM)$-1.04B$3.88B
Revenue (TTM)$0$12.95B
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)--+11.8%
Gross margin--85.5%
Operating margin--33.1%
Net margin--30.7%
Free cash flow (TTM)$-473.17M$3.20B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership94.3%96.8%
Insider activity (12mo)37 buy / 9 sell28 buy / 22 sell
Short interest (% of float)9.9%1.9%
Analyst consensus73% buy / 18% hold / 9% sell (11)95% buy / 5% hold (21)
Analyst price target$29 (+131%)$624 (+21%)
StockVane view
StockVane Quant RatingC (76)C (68)
Company
Employees2746,400
Founded20221989

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.